The purpose of this randomized study is to determine whether a community-based test and treat
model of hepatitis C (HCV) care delivery will be superior to the usual care practice of
referral to specialist clinics for the outcomes of sustained virologic response at 12 weeks
after treatment and initiation of HCV treatment for persons who inject drugs (PWID) between
ages 18 and 29 who are naïve to HCV treatment
Phase:
Phase 4
Details
Lead Sponsor:
Weill Medical College of Cornell University
Collaborator:
Gilead Sciences
Treatments:
Sofosbuvir Sofosbuvir-velpatasvir drug combination Velpatasvir